Scientists at the University of California, Davis have discovered a new way to create drug-like compounds that could treat depression, PTSD, and addiction without causing the intense hallucinations associated with traditional psychedelics. This breakthrough, published in the Journal of the American Chemical Society, opens the door to a completely new class of medications that might help millions of people struggling with mental health conditions.

The research team used ultraviolet light to transform amino acids — the building blocks of proteins — into molecules that act like psychedelics in the brain. These new compounds target serotonin 5-HT 2A receptors, which are known to promote brain cell growth and are considered promising targets for treating several serious mental health disorders. However, unlike classic psychedelics such as LSD or psilocybin, these new molecules did not produce hallucinogenic-like behaviors in animal testing.

What This Means for People With Depression and PTSD

For the estimated 21 million adults in the United States who experience at least one major depressive episode each year, current treatment options often fall short. Antidepressants like SSRIs can take weeks to work and may cause side effects such as weight gain, sexual dysfunction, and emotional numbness. Psychedelic-assisted therapy has shown remarkable promise in recent clinical trials, but the powerful hallucinations can be frightening for some patients and require careful medical supervision.

If these new compounds prove safe and effective in humans, they could offer a middle ground — the mood-boosting and brain-healing benefits of psychedelics without the disorienting trips. This could make treatment more accessible and less intimidating for people who might otherwise avoid psychedelic therapy.

The Big Question: Can We Separate the Trip From the Treatment?

Researchers have long wondered whether the hallucinogenic effects of psychedelics are necessary for their therapeutic benefits. Some experts believe the profound, often life-changing experiences during a psychedelic trip are essential for healing. Others argue that the biological changes happening in the brain — such as increased connectivity between neurons and the growth of new brain cells — are what truly matter.

This new study suggests that the second view may be correct. The UC Davis team created a compound called D5 that fully activates the same serotonin receptor targeted by psychedelics. In laboratory tests, D5 showed activity levels ranging from 61% to 93%, with the strongest version acting as a full agonist — meaning it triggered the maximum possible biological response from the receptor system.

Despite this strong activation, mice given D5 did not display the head twitch response that scientists use as a standard indicator of hallucinogenic-like effects. This finding challenges the assumption that activating the 5-HT 2A receptor always leads to hallucinations.

How the New Compounds Were Created

The research team, led by Ph.D. students Joseph Beckett and Trey Brasher under Professor Mark Mascal at the UC Davis Department of Chemistry, took an innovative approach to drug discovery.

• Starting materials: The scientists combined several amino acids with tryptamine, a naturally occurring metabolite derived from the essential amino acid tryptophan.
• Light activation: They exposed the resulting molecules to ultraviolet light, which triggered chemical changes that produced entirely new compounds.
• Computer screening: Using computer modeling, the team evaluated how strongly 100 of the new compounds interacted with the brain’s 5-HT 2A serotonin receptor.
• Laboratory testing: From that group, five compounds were selected for more detailed testing. Their activity levels ranged from 61% to 93%.

“In medicinal chemistry, it’s very typical to take an existing scaffold and make modifications that just tweak the pharmacology a little bit one way or another,” said study author Trey Brasher. “But especially in the psychedelic field, completely new scaffolds are incredibly rare. And this is the discovery of a brand-new therapeutic scaffold.”

What Experts Say About This Approach

Mental health professionals and neuroscientists have been cautiously optimistic about the potential of non-hallucinogenic psychedelic-like drugs. Dr. David Olson, a chemical neuroscientist at the University of California, Davis who was not involved in this study, has previously described these types of compounds as “psychoplastogens” — drugs that promote rapid neural plasticity without causing hallucinations.

Many experts agree that the current mental health crisis demands new solutions. Traditional antidepressants work for only about 60-70% of people who try them, and even then, they often take weeks to produce noticeable improvement. Psychedelic treatments, while promising, require expensive and time-consuming therapy sessions and aren’t suitable for everyone.

The UC Davis team’s discovery of a completely new molecular scaffold — the basic structure around which drugs are built — is particularly exciting because it provides a fresh starting point for drug development. Most existing psychedelic-like drugs are variations on a few known chemical structures. This new scaffold could lead to medications with different properties, potentially fewer side effects, and better safety profiles.

How This Could Affect Your Health

While these findings are still in the early research stage, they point toward a future where mental health treatment might include medications that:

• Work faster than traditional antidepressants, possibly within hours or days instead of weeks
• Promote brain cell growth and repair connections damaged by chronic stress or trauma
• Cause fewer side effects than current psychedelic therapies, which can include anxiety, confusion, and frightening hallucinations
• Be easier to administer in a doctor’s office or even at home, without the need for intensive supervision

It’s important to note that these compounds have only been tested in laboratory settings and in mice. Human clinical trials are still years away. The research team now plans to investigate whether other serotonin receptors may be reducing or blocking the hallucinogenic-like effects produced by D5.

“We determined that the scaffold itself possesses a range of activity,” Brasher said. “But now it’s about elucidating that activity and understanding why D5 and similar molecules are non-hallucinogenic when they’re full agonists.”

Practical Takeaways for Readers

If you or someone you love is struggling with depression, PTSD, or substance use disorder, here’s what you should know about this research:

• This is early-stage science. Promising laboratory results don’t always translate to effective human treatments. It typically takes 10-15 years for a new drug to move from discovery to pharmacy shelves.
• Don’t stop your current treatment. If you’re taking antidepressants or participating in therapy, continue as prescribed. These new compounds are not available and may never be approved for use.
• Talk to your doctor about clinical trials. If you’re interested in cutting-edge treatments, ask your healthcare provider about ongoing studies for depression, PTSD, or addiction.
• Stay informed but skeptical. Headlines about “miracle drugs” often oversimplify complex science. Trust reputable sources like university news outlets and peer-reviewed journals.
• Consider lifestyle factors. While researchers search for better medications, proven approaches like regular exercise, adequate sleep, healthy eating, and social connection remain powerful tools for mental health.

What Happens Next

The UC Davis team, in collaboration with researchers at the Medical College of Wisconsin and UC San Diego, will continue studying D5 and similar molecules. They want to understand exactly why these compounds don’t cause hallucinations despite strongly activating the same receptor as classic psychedelics.

The research was funded by grants from the National Institutes of Health and the Source Research Foundation. Additional authors on the paper include Mark Mascal, Lena E. H. Svanholm, Marc Bazin, Ryan Buzdygon, Steve Nguyen, John D. McCorvy, Allison A. Clark, Serena S. Schalk, Adam L. Halberstadt, and Bruna Cuccurazza.

For now, this discovery represents an important step forward in the search for better mental health treatments. As Beckett and Brasher explained, “Laboratory and computational studies showed that these molecules can partially or fully activate serotonin signaling pathways linked to both brain plasticity and hallucinations, while experiments in mice demonstrated suppression of psychedelic-like responses rather than their induction.”

The question that drove this research — “Is there a whole new class of drugs in this field that hasn’t been discovered?” — now has a clear answer. “The answer in the end was, ‘Yes,'” said Beckett. The challenge ahead is turning that yes into a treatment that can help people who are waiting for better options.

Source: ScienceDaily